All Blogs

Jul 11, 2018

Jul 10, 2018

Arming antibiotics with a vaccination-like immune response Harnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these microorganism perpetually evolv...

Jul 10, 2018

Jul 09, 2018

Allergic Conjunctivitis (AC) is a common eye disorder characterized by the inflammation in the tissue that lines the inside of eyelid and outside of the eyeball called conjunctiva. It usually happens when a person’s eyes come into contact with an allergen, a substance that makes the body’s immune system to overreact...

Jun 22, 2018

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic re...

Jun 21, 2018

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

Jun 18, 2018

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory response and cellular responses. NF-κB is also involved in producing the synergistic immune responses. NF...

Jun 14, 2018

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...

Jun 07, 2018

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation stu...

Jan 06, 2025

Parkinson's disease and tuberculosis are two significant health challenges that affect millions worldwide. Recent research has unveiled a fascinating connection between these two diseases through a common protein known as Parkin. Understanding this link not only sheds light on the mechanisms of both diseases but al...